ESTRO 35 2016 ______________________________________________________________________________________________________ radiotherapy (50.2Gy/27#, 50Gy/25# or 45Gy/25#) followed by brachytherapy (26Gy/4# or 28Gy/4# to HRCTV). In the current study the original treatment plans were re-optimised, using Brachyvision Version 11. The aim was to escalate the GTV(BT) dose to 140% of the original HRCTV prescription dose (8.4Gy and 9.8Gy/# respectively), keeping the HRCTV coverage and organ at risk DVH values within the tolerance which had been accepted for the original clinical plans. GTV (BT) and HRCTV were drawn according to GEC-ESTRO recommendations. The relationship between the volumes can be defined by the following equation. HRCTV2 = HRCTV1 -GTV(BT) The quality of the re-optimised plans was quantified by using dose volume histogram parameters. Table 1 shows a comparison of the original and the re-optimised plan parameters.In 10 out of the 14 cases (71.4%) more than 90% of the GTV(BT) was covered by the 140% isodose after re-optimisation.The HRCTV1 V100% was reduced for the re-optimised plans by an average of 2.95% (range 0.7-6.01%).Average coverage of HRCTV2 with the prescription isodose was 94.5% for the 6Gy plans, and 81.7% for the 7Gy plans.In 12 out of the 14 cases (85.7%) the treatment time was reduced with the boost plan.
Conclusion:
It is possible to boost the prescription dose to the GTV(BT) to 140% for treatment plans with interstitial catheters and IU within the GTV(BT) volume. Plans without both interstitial catheters and IU in the GTV(BT) are most likely to be suboptimal. This planning study demonstrates that dose escalation to the GTV(BT) is feasible if clinically indicated, and further work into clinical application and outcome should be considered.
PO-0958
Locally advanced cervical cancer treated with IGABT: impact of the D90 HR-CTV on patterns of relapse Purpose or Objective: Locally advanced cervical cancer patients with a bulky high-risk clinical target volume (HR-CTV) get the largest benefit of dose escalation in terms of local control. But the expected survival benefit could be lessened by a higher metastatic risk. We examined the patterns of relapse according to the HR-CTV and to the ability to reach the target dose.
Material and Methods:
Pts treated with chemoradiation between 04/2007 and 02/2012 were included if they had a disease limited to the pelvis after an exhaustive primary staging (PET/CT plus primary laparoscopic para-aortic lymphadenectomy) and if they had received concurrent chemotherapy. Pts received pelvic irradiation (45 Gy) then a PDR brachytherapy boost +/-a pelvic sequential boost for PET positive pelvic lymph nodes. First sites of relapse were examined.
Results: 109 pts were included, with median follow-up of 39 months. Median D90 HR-CTV was 73.5 Gy in case of HR-CTV ≥ 30 cm3 (n = 28) versus 86.4 Gy in case of HR-CTV < 30 cm3 (p < 0.001). Pts with a not-bulky HR-CTV (< 30 cm3) experienced local failure in 5/81 (6.2%), versus in 6/28 (21.4 %) in case of bulky HR-CTV (p = 0.03), but the HR-CTV volume did not correlate with the risk of local failures as only events. Pts with a bulky HR-CTV volume had a higher risk of distant failures: 10/28 (35.8 %) versus 7/81 (8.6 %) in case of notbulky HR-CTV (p = 0.002). Local failures were seen in 3/47 (6.4 %) for pts with a D90 HR-CTV ≥ 85 Gy and in 8/62 (12.9 %) for pts with a D90 HR-CTV < 85 Gy, respectively (p=0.055). Distant failures were seen in 1/47 (2.1 %) and in 16/62 (25.8 %), respectively (p<0.001). This higher frequency of distant events in pts with a D90 HR-CTV < 85 Gy remained significant after exclusion of local failures: 0/44 (0 %) versus 11/54 (20.4 %), respectively (p < 0.001).
Conclusion:
The inability to reach the target dose seems correlated with a higher propensity to metastases. Strategies integrating the metastatic risk are mandatory for maximizing the benefit of dose escalation.
PO-0959
Dosimetric outcome and perioperative toxicity using Utrecht applicator in cervical brachytherapy F.J. Celada Alvarez Purpose or Objective: GEC-ESTRO recommendations for IGRT in brachytherapy, the incorporation of MRI in the planning and new MRI-compatible applicators have improved our treatments. But, in big tumours, intrauterine applicators don´t seem enough in order to reach a good coverage. Interstitial CT-MRI Utrecht (Elekta®) applicator with plastic needles lets improve HR-CTV and IR-CTV coverage sparing organs at risk. However, a further complication using interstitial applicators may be gynaecological bleeding during the withdrawal of the applicator. The purpose of this study is to review perioperative toxicity and dosimetry in patients with cervix tumours using interstitial CT-MRI Utrecht applicator.
Material and Methods:
Retrospective review of the records of 122 cervical cancer patients treated in our institution from ________________________________________________________________________________ February´10 to September´15. To be included in the study, the treatment had to fulfill the criteria: (1) include a previous treatment of at least 45Gy of EBRT to the pelvis concomitant with cisplatin; (2) the BT boost consisted in insertion of interstitial Utrecht applicator under spinal anesthesia and individualized MRI planning. Each treatment was composed of 2 applications (7 days apart), with 2 separated fractions (in 24 hours) of nominal 7 Gy (the aim is to obtain the HR-CTV and IR-CTV D90 higher than 85 and 65 Gy EQD2 respectively keeping the OAR doses as low as possible with limits of D2cc of rectum and sigmoid lower than 70 Gy EQD2 and 85 Gy EQD2 in case of bladder). Applicator withdrawal was performed at the surgical theatre. Toxicity score (gynaecological bleeding) were defined by CTCAE v4.0.
Results: 110/122 (90.16%) patients were IIB stage or bigger, and in 68% of patients 6 needles were inserted in both applications. Median tumour volume at diagnoses was 39.8 cc (8.79-205) and median HR-CTV volume at first application was 18.01 cc (7.36-116.59). The final median biologically equivalent doses (EQD2) were D90 HR-CTV = 89.75 Gy10 (78.50-94.00) and D90 IR-CTV = 67.90 Gy10 (58.60-77.40). For the first application, needles were used in all patients, and 4 (3.2%) patients required vaginal tamponade and/or stitch (Grade 2 CTCAE v4.0), and 2 (1.6%) patients required transfusion and/ or endoscopic intervention (Grade 3 CTCAE v4.0). For the second application, needles were used in 114 patients, and 5 (4.3%) patients required vaginal tamponade and/or stitch (Grade 2 CTCAE v4.0) without bigger toxicities.
Conclusion:
Our results suggest that interstitial IGBT as recommended by the GEC-ESTRO, is a safe option without life-threatening consequences due to bleeding, and dosimetric results compare favorably with the traditional technique. Purpose or Objective: MR-guided brachytherapy (MRgBT) improves local control and survival in patients with cervical cancer. It is expected that MRgBT will be standard of care within 5 years. MRgBT is more demanding of resources and optimized processes will be of great importance in assuring its widespread availability. Our aim was to determine the value of imaging and adaptive replanning prior to each MRgBT fraction compared to a less resource intensive approach tailored to specific technique considerations.
PO-0960

Material and Methods:
A total of 20 patients with cervical cancer who received external beam radiotherapy (EBRT: 45-50.4 Gy in 1.8-2 Gy fractions) and high dose rate MRgBT (28 Gy in 4 fractions using 2 insertions) were included in this study. A tandem/ring applicator (TR) was used in 9 patients, and a TR with interstitial needles in 4 patients for all 4 fractions. In 3 of these 4 patients, further plan adaptation with increase in number of needles was performed for fractions 3 and 4. In the remaining 7 patients, a TR alone was used for fractions 1 and 2 and a TR plus needles for fractions 3 and 4 to improve target coverage or OAR sparing. All patients underwent MR imaging, contouring and planning prior to each fraction. To simulate a more efficient approach with only one plan per insertion, optimized fraction 1 plan was applied to fraction 2 anatomy, and optimized fraction 3 plan was applied to the fraction 4 anatomy. To assess value of plan adaptation, projected total dose from first insertion was compared to the final total dose following plan adaptation.
Results: There was no systematic change in the high-risk clinical target volume (HRCTV) across fractions (mean range 41-44 cm3). Mean cumulative HRCTVD90 with daily plan optimization was 92 Gy10, and the mean rectal, sigmoid and bladder D2cc doses were 67, 65 and 83 Gy3 respectively. There were no clinically significant changes in the mean HRCTV or OAR D2cc doses with only two plans prior to fractions 1 and 3. The GEC-ESTRO HRCTV target dose >85 Gy10 was achieved in 16/20 patients with either daily plan optimization or planning only twice. All GEC-ESTRO OAR target doses (rectum <75 Gy3, sigmoid <75 Gy3, bladder <90 Gy3) were achieved in 14/20 patients with optimized daily replanning, and this was maintained when only two plans were used. Plan adaptation with addition of interstitial needles for second insertion resulted in improved HRCTVD90 dosimetry in 6/10 cases and in improved OAR dosimetry in 4/10 cases.
Conclusion:
MRgBT can potentially improve outcomes of cervical cancer patients but is more resource intensive. This study suggests that improvements in efficiency can be achieved through process analysis and optimization. While adaptive MR-based replanning is fundamental to achieving the benefits of MRgBT, replanning at strategic intervals may be as effective as daily replanning with considerable savings in resources. 
PO-0961
Material and Methods:
We analyzed the data of six patients with cervical carcinoma, receiving a 192Ir HDR brachytherapy treatment. The dose was delivered with a micro-Selectron afterloader. A treatment plan was performed using both the TG43 and TG186 dose calculation methods of the Oncentra Brachy v4.5 treatment planning system (TPS). Two cylindrical applicators, of 30 mm and 35 mm diameter were used: the Vaginal Applicator Set and the Shielded Cylindrical Applicator Set, by Nucletron. The treatment dose is prescribed at 0.5 cm distance from the cylinder wall (prescription point), with a treated extension of 3 cm. Analysis included dose volume histograms (DVH) for bladder and rectum and prescription point, according to American Brachytherapy Society (ABS) consensus guidelines (2012). The TG186 results were obtained using the standard accuracy level option of modelbased algorithm (Oncentra Brachy-Advanced Collapsed cone Engine (ACE), Elekta), resulting in calculation times on the order of 40 s.
